Author Archives: Teresa Carvalho

Landos, Johns Hopkins Partner to Advance Potential MS Oral Therapy

Landos Biopharma has entered into a research partnership with Johns Hopkins University School of Medicine focused on advancing LABP-66 as a potential oral, once-daily therapy for multiple sclerosis (MS) and other disorders, the company announced. LABP-66 is a lab-made molecule that activates NLRX1, a receptor that is key in…

MSAA Is ‘Improving Lives Through Art’

The Multiple Sclerosis Association of America (MSAA) is inviting people to participate in its Improving Lives Through Art Series, a cycle of virtual fundraising events starting Sept. 14. The kick-off event of this four-part fall series is a virtual follow-along painting experience. Tickets can be purchased here…

Safety Board Says Phase 2 Temelimab Trial Should Move Forward

A Phase 2a clinical trial evaluating GeNeuro‘s investigational antibody temelimab as a treatment for relapsing multiple sclerosis (MS) should continue as planned, without modifications. That’s the recommendation of a Drug Safety Monitoring Board, an independent committee of clinical research experts, which was evaluating the trial of the…

Online Art Auction Supports National MS Society

An online auction event supporting the National Multiple Sclerosis Society  is is running through Feb. 13 on Facebook. Organized by The Dyeing Arts group, the fundraising auction features tie dye and handcraft art from several online communities. The event arose from a partnership between Lighthouse Outdoor Products…

New Study Will Assess Tysabri Effects on MS Cognitive Fatigue

Researchers from the Kessler Foundation will launch a new study investigating the effects of Tysabri (natalizumab) on cognitive fatigue — the type of fatigue that happens after strong mental concentration, such as in problem-solving — in people with relapsing-remitting multiple sclerosis (RRMS). Cognitive fatigue, which is very…

Start2Cure Foundation Awards Grant to MS Gene Therapy Project

Start2Cure Foundation is funding a research project that will investigate the potential of a gene therapy approach to treat multiple sclerosis (MS). MS is an autoimmune disease characterized by the damage and loss of myelin — the protective layer around nerve fibers, or axons, that is crucial to the…

Tysabri Superior to Gilenya at Easing Activity in RRMS, Study Reports

Treatment with Tysabri (natalizumab) was more effective than Gilenya (fingolimod) in helping people with relapsing–remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…

Newly Discovered Type of Immune Cells May Be Key in Treating MS

A recently identified group of immune cells saved damaged nerve cells from death and promoted nervous system repair, a new study suggests. This finding may represent new promise for treating neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The study, “A new neutrophil…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Video